News

Type C meeting with the FDA requested by Allarity to discuss potential clinical paths to support approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma

The combination of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone bests the CHOP regimen in the treatment of patients with peripheral T-cell lymphoma.

Adding toripalimab to chemotherapy as frontline treatment for advanced non–small cell lung cancer crossed the boundary for statistical significance in CHOICE-01, meeting 2 study end points.

Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.

All primary end points in the phase 3 study of bempegaldesleukin plus nivolumab for the treatment of metastatic melanoma were missed, but analyses are ongoing.

Tracy Rose, MD, discussed the future of adjuvant and neoadjuvant therapy in muscle-invasive bladder cancer specifically using cisplatin-based regimens.

The AALL1231 trial of bortezomib showed survival benefit for children with T-cell lymphoblastic lymphoma and significantly reduced need for cranial radiotherapy in patients with T-cell acute lymphoblastic leukemia.

Carole Miller, MD, discusses the REVEAL study which enrolled patients with polycythemia vera at both academic and community practices.

An update from the phase 2 AMEERA-3 clinical trial shows that amcenestrant does not improve progression-free survival in ER-positive, HER2-negative breast cancer.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.

Cathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.

Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

FDA approval has been granted to adjuvant olaparib for the treatment of BRCA-mutated, HER2-negative breast cancer.

Showing similarity to results from CheckMate 214, findings from CheckMate 920 shows that nivolumab plus ipilimumab can safety be administered to patients with non-clear cell renal cell carcinoma.

Orphan drug designation has been granted to HT-KIT from the FDA for the treatment of mastocytosis

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.

Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.

Oncologists at FCS, Lucio N. Gordan, MD and Ivor Percent, MD have published findings from the CheckMate 920 clinical trial.

Florida Cancer Specialists shares profile of Katy Phelan, PhD, the director of the organizations Genetics Laboratory.

A multivariate analysis of response rates of patients with metastatic renal cell carcinoma identified which factors are associated with a partial or complete response to first-line doublet immunotherapy or immunotherapy/tyrosine kinase inhibitor combinations.

Following positive early results from the ASPEN-01 clinical trial, the first patient with HER2-positve gastric or gastroesophageal cancer has received the experimental combination of evorpacept, trastuzumab, ramucirumab, and paclitaxel in ASPEN-06.

Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.

Findings from the GALAHAD clinical trial highlight the importance of molecular testing to inform treatment and disease management decision for prostate cancer.

Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.

A supplemental new drug application seeking FDA approval for darolutamide and docetaxel for the treatment of patient with metastatic hormone-sensitive prostate cancer has been submitted.

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

Srdan Verstovsek, MD, discussed the ways in which ropeginterferon and rusfertide can reduce thromboembolic events in polycythemia vera.

In the phase 3 TROPICS-02 clinical trial, sacituzumab govitecan demonstrated a 30% reduction in the risk of disease progression or death versus chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.